RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
27 hedge funds and large institutions have $252M invested in RAPT Therapeutics in 2019 Q4 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
5.23% more ownership
Funds ownership: 0% → 5.23% (+5.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PS
Peter Svennilson
|
+$156M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.2M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
+$19.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.31M |
| 5 |
BlackRock
New York
|
+$1.36M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | +$2.39K | +13 | New |
|
|
LTFS
27
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | +$736 | +4 | New |
|
RAPT Hedge Fund Activity: Q4 2019 in Review
27 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q4 2019, worth a combined $252M.
Buyers outnumbered sellers: 27 funds opened new RAPT positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Peter Svennilson, opening a new position worth an estimated $156M.
- 27 institutional investors held RAPT Therapeutics (RAPT) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $252M of RAPT Therapeutics stock for Q4 2019.
- 27 funds opened new RAPT Therapeutics positions in Q4 2019 and 0 closed out, a net change of +27 holders.
- The largest RAPT Therapeutics buyer in Q4 2019 was Peter Svennilson, an estimated $156M added.
Based on aggregated 13F filings for Q4 2019.